Biomarkers for Assessing Beta7 Integrin Antagonist Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective biomarkers for assessing the efficacy, safety, and dosing of therapeutic agents like integrin beta7 antagonists for treating gastrointestinal inflammatory disorders, such as Crohn's disease and ulcerative colitis, which hinders personalized treatment approaches.
Innovation Solution
The use of gut-homing lymphocytes, drug occupancy on these cells, and beta7 integrin receptor levels as biomarkers to evaluate treatment response, design treatment regimens, and adjust dosing in patients, allowing for personalized medicine strategies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional treatment assessment methods are used for gastrointestinal inflammatory disorders, then treatment can be administered, but the ability to predict treatment efficacy and adjust dosing is insufficient
Solution Approach 1:
The patent introduces biomarkers (gut-homing lymphocytes, beta7 integrin receptors, and drug occupancy levels) as intermediary substances that mediate between the therapeutic agent and the patient's physiological response. These biomarkers serve as measurable indicators that bridge the gap between administering treatment and predicting efficacy, allowing for precise assessment without direct measurement of treatment effect on disease markers.
Solution Approach 2:
The patent implements feedback mechanisms by measuring biomarker levels before and during treatment to predict and monitor treatment response. The biomarker data provides feedback that enables adjustment of dosing and treatment strategy, creating a closed-loop system that continuously refines treatment optimization based on real-time patient response information.
2Adaptability or versatility
If personalized treatment regimens are implemented, then treatment efficacy can be optimized, but the complexity of treatment design and monitoring increases
Solution Approach 1:
The patent segments the complex treatment monitoring process into distinct measurable components: gut-homing lymphocyte levels, beta7 integrin receptor expression, and drug occupancy percentages. By dividing the overall treatment assessment into these separate, independently measurable biomarkers, the system reduces the complexity of monitoring while enabling personalized treatment adjustments based on individual patient responses to each specific marker.
3Reliability
If biomarker measurement is performed frequently to monitor treatment response, then treatment optimization is improved, but the time and resources required for monitoring increase
Solution Approach 1:
The patent applies preliminary action by measuring biomarker levels (particularly gut-homing lymphocytes and beta7 integrin receptors) before initiating treatment to establish baseline values that predict treatment response. This pre-treatment assessment allows for prediction of efficacy without requiring continuous monitoring during the treatment period, reducing the time and resources needed for ongoing monitoring while maintaining reliable prediction capability.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention is directed to methods of using biomarkers to assess treatment of gastrointestinal inflammatory disorders with beta7 antagonists. More particularly, the present invention relates to methods of using the level of gut-homing lymphocytes in peripheral blood, the level of drug occupancy on gut-homing lymphocytes, and/or the level of beta7 integrin receptors on gut-homing lymphocytes as indicators (or biomarkers) of the effect, efficacy, safety, prognosis, and/or dosing of therapeutic agents, such as beta7 integrin antagonists, for the treatment of gastrointestinal inflammatory disorders.